This year we got an early holiday treat with the approval of Restylane Refyne and Restylane Defyne hylarounic acide dermal fillers. These new fillers are the perfect complement to the rest of the Restylane family of products by Galderma. While they are new additions in the US, they have a proven track record in the filler market overseas. They received approval in Europe in 2010 under the name Emervel and then later debuted in Canada under the same name.
Restylane Refyne and Restyane Defyne are advanced H
A (Hylarounic Acid) gel fillers that are approved for use in moderate to severe facial wrinkles. These next generations of dermal filler are designed using a unique manufacturing process called XpresHAn technology. XpresHAn Technology used in the HA gel of Refyne and Defyne customizes the cross-linking of the HA in the products. This allows for the creation of different gel textures to adapt to each skin texture needs, providing flexibility and support for a variety of lines, folds and areas of volume loss. Studies show that Refyne and Defyne are proven to last up to 12 months.
Restylane Refyne and Restylane Defyne will be available in the 1st Quarter of 2017 here in the United States. Rand Rusher RN CANS is a national trainer for Galderma and will be presenting Restylane at the GAIN Train. RR Aesthetic will be one of the 1st office to receive the product. Rand hand trains our team of injectable experts including Jennifer Izzarelli NP CANS and Michele Florez RN CANS. RR Aesthetic’s Medical Director, Dr Carlo Honrado, leads the team in all advanced aesthetic procedures on the market.